Abstract
Interview with Dr. Carl June on chimeric antigen receptor therapy. (09:04)Download This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors. Toxic effects of chimeric antigen receptor therapies include cytokine release syndrome and neurologic dysfunction.
Keywords
Chimeric antigen receptorMedicineCytokine release syndromeAntigenImmunologyRefractory (planetary science)ImmunotherapyReceptorImmune systemInternal medicineBiology
MeSH Terms
Adoptive TransferAntigensCD19Genetic EngineeringHumansNeoplasmsReceptorsAntigenT-CellRecombinant Fusion ProteinsRemission InductionT-Lymphocytes
Affiliated Institutions
Related Publications
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whet...
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that...
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use o...
Cytokine release syndrome
During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell eng...
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost ...
Publication Info
- Year
- 2018
- Type
- review
- Volume
- 379
- Issue
- 1
- Pages
- 64-73
- Citations
- 2080
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2080
OpenAlex
65
Influential
1923
CrossRef
Cite This
Carl H. June,
Michel Sadelain
(2018).
Chimeric Antigen Receptor Therapy.
New England Journal of Medicine
, 379
(1)
, 64-73.
https://doi.org/10.1056/nejmra1706169
Identifiers
- DOI
- 10.1056/nejmra1706169
- PMID
- 29972754
- PMCID
- PMC7433347